NCT05588141 2026-04-16
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
Clinical Trials
29 trialsNCT06721689 2026-04-15
PEEL-224
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT07242963 2026-04-13
Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
Baylor College of Medicine
Recruiting
NCT03970447 2026-04-08
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
NCT07502287 2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2 Recruiting
NCT05184816 2026-03-27
A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT05283330 2026-03-20
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
Phase 1 Recruiting
NCT06161519 2026-03-19
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT01356290 2026-02-23
MEMMAT
Medical University of Vienna
Phase 2 Recruiting
NCT05124912 2026-02-20
REMASTer: REcurrent Brain Metastases After SRS Trial
Monteris Medical
Phase NA Recruiting
NCT07263438 2026-02-13
Phenix
Centre Hospitalier Universitaire Vaudois
Phase 2 Recruiting
NCT05629702 2026-01-30
ARISTOCRAT
University of Birmingham
Phase 2 Recruiting
NCT06208657 2026-01-28
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
Phase 1/2 Recruiting
NCT05084430 2026-01-22
Study of Pembrolizumab and M032 (NSC 733972)
University of Alabama at Birmingham
Phase 1/2 Recruiting
NCT05366179 2025-10-20
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT04337177 2025-09-23
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Phase 1 Recruiting
NCT03672721 2025-08-11
IA Carboplatin + Radiotherapy in Relapsing GBM
Université de Sherbrooke
Phase 1/2 Recruiting
NCT06356883 2025-08-07
Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
Université de Sherbrooke
Phase 2 Recruiting
NCT06430424 2025-07-30
GBrecurr
University Hospital, Bordeaux
Recruiting
NCT05432518 2025-04-25
Pilot Trial for Treatment of Recurrent Glioblastoma
AHS Cancer Control Alberta
Phase EARLY_PHASE1 Recruiting
NCT06674265 2025-04-09
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
Kian Immune Cell Company
Phase 1 Recruiting
NCT06751134 2025-02-07
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
Nanjing Children's Hospital
Phase 1 Recruiting
NCT06801730 2025-01-30
NALIRIBVRG
The Central Hospital of Lishui City
Phase 2 Recruiting
NCT06684639 2024-12-20
A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma
The General Hospital of Western Theater Command
Phase EARLY_PHASE1 Recruiting
NCT04267978 2024-10-15
Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas
Beijing Sanbo Brain Hospital
Phase 2 Recruiting
NCT05868928 2024-05-14
Imaging Features for the Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis
Asan Medical Center
Recruiting
NCT06273176 2024-02-22
RECMAP
Erasmus Medical Center
Recruiting
NCT04931732 2023-10-11
circTeloDIAG
Hospices Civils de Lyon
Recruiting